{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T10:34:00Z","timestamp":1761129240962,"version":"3.37.3"},"reference-count":19,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","award":["IISP 50235"],"award-info":[{"award-number":["IISP 50235"]}],"id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["K24 AI085118"],"award-info":[{"award-number":["K24 AI085118"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Transplant Infectious Dis"],"published-print":{"date-parts":[[2015,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Posaconazole (<jats:styled-content style=\"fixed-case\">PCZ<\/jats:styled-content>) has become an attractive alternative to voriconazole (<jats:styled-content style=\"fixed-case\">VCZ<\/jats:styled-content>) in transplant recipients with suspected or proven invasive filamentous fungal infections, causing fewer drug interactions. Here, we describe our experience with <jats:styled-content style=\"fixed-case\">PCZ<\/jats:styled-content> after <jats:styled-content style=\"fixed-case\">VCZ<\/jats:styled-content> in solid organ transplant (<jats:styled-content style=\"fixed-case\">SOT<\/jats:styled-content>) recipients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p><jats:styled-content style=\"fixed-case\">VCZ<\/jats:styled-content> was replaced by <jats:styled-content style=\"fixed-case\">PCZ<\/jats:styled-content> liquid solution in 19 <jats:styled-content style=\"fixed-case\">SOT<\/jats:styled-content> recipients (15 lung, 2 kidney, 1 liver, and 1 heart\/lung) with invasive pulmonary aspergillosis (12\/19; 63.2%), possible invasive pulmonary fungal infection (2\/19; 10.5%), prophylaxis (2\/19; 10.5%), or pulmonary scedosporiosis, mucormycosis, and mixed fungal species (1 each). Rationales for switch were suspected adverse reactions to <jats:styled-content style=\"fixed-case\">VCZ<\/jats:styled-content> (17\/19; 89.4%) and desire to broaden spectrum of coverage to include agents of mucormycosis (3\/19; 15.8%).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p><jats:styled-content style=\"fixed-case\">PCZ<\/jats:styled-content> was well tolerated in all patients. In those patients with baseline liver enzyme abnormalities, a median change occurred in concentrations of alanine transaminase (\u221220\u00a0IU\/L), aspartate aminotransferase (\u221217.5\u00a0IU\/L), and alkaline phosphatase (\u221261.5\u00a0IU\/L). Clinical success (resolution, stabilization, or prevention of infection) was achieved in 16\/19 (84%) people.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p><jats:styled-content style=\"fixed-case\">PCZ<\/jats:styled-content> appears to have a reasonable safety and tolerability profile and may be an effective alternative in <jats:styled-content style=\"fixed-case\">SOT<\/jats:styled-content> patients who require an agent with anti\u2010mold activity, but are unable to tolerate <jats:styled-content style=\"fixed-case\">VCZ<\/jats:styled-content>.<\/jats:p><\/jats:sec>","DOI":"10.1111\/tid.12389","type":"journal-article","created":{"date-parts":[[2015,4,6]],"date-time":"2015-04-06T13:40:32Z","timestamp":1428327632000},"page":"493-496","source":"Crossref","is-referenced-by-count":6,"title":["Posaconazole liquid suspension in solid organ transplant recipients previously treated with voriconazole"],"prefix":"10.1111","volume":"17","author":[{"given":"S.","family":"Shoham","sequence":"first","affiliation":[{"name":"Transplant and Oncology Infectious Diseases Program Johns Hopkins University School of Medicine Baltimore Maryland USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Ostrander","sequence":"additional","affiliation":[{"name":"Transplant and Oncology Infectious Diseases Program Johns Hopkins University School of Medicine Baltimore Maryland USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Marr","sequence":"additional","affiliation":[{"name":"Transplant and Oncology Infectious Diseases Program Johns Hopkins University School of Medicine Baltimore Maryland USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2015,6]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1086\/504328"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1086\/508774"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0b013e3181837585"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/myc.12023"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1086\/430068"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1086\/500212"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1086\/588660"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/1469-0691.12465"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/1469-0691.12371"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/1469-0691.12515"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1086\/525258"},{"key":"e_1_2_6_13_1","doi-asserted-by":"crossref","first-page":"2950","DOI":"10.1128\/JCM.36.10.2950-2956.1998","article-title":"Comparison of in\u00a0vitro activities of the new triazole SCH56592 and the echinocandins MK\u20100991 (L\u2010743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts","volume":"36","author":"Espinel\u2010Ingroff A","year":"1998","journal-title":"J Clin Microbiol"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.7.2151-2153.2001"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.3109\/1040841X.2012.711741"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11046-014-9792-y"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1086\/657306"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2012.04042.x"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiu017"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1159\/000359952"}],"container-title":["Transplant Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Ftid.12389","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/tid.12389","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T10:10:15Z","timestamp":1696155015000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/tid.12389"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6]]},"references-count":19,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["10.1111\/tid.12389"],"URL":"https:\/\/doi.org\/10.1111\/tid.12389","archive":["Portico"],"relation":{},"ISSN":["1398-2273","1399-3062"],"issn-type":[{"type":"print","value":"1398-2273"},{"type":"electronic","value":"1399-3062"}],"subject":[],"published":{"date-parts":[[2015,6]]}}}